Kementerian Kesehatan Republik Indonesia Penilaian Teknologi Kesehatan

Rosuvastatin untuk pencegahan sekunder penyakit kardiovaskular

Penilaian teknologi kesehatan PTK-C10AA07 Draf untuk telaah Diperbarui 30 Juli 2026

1. Hasil kasus dasar

StrategiBiaya terdiskontoQALY terdiskontoTahun hidup
Rosuvastatin 20 mgRp 82,3 juta10,18718,45
simvastatin 20 sampai 40 mgRp 81,5 juta10,03418,16
SelisihRp 813.5750,153-

2. Analisis probabilistik

Bidang efektivitas biaya. Setiap titik adalah satu simulasi probabilistik. Titik di bawah sumbu nol berarti intervensi menurunkan biaya.
-10-505100,000,100,200,30Tambahan tahun hidup berkualitas per pasien (QALY)Tambahan biaya per pasien (juta rupiah)1 kali PDB per kapita3 kali PDB per kapita
  • Simulasi probabilistik (500 sampel)
  • Kasus dasar
Kurva penerimaan. Peluang intervensi hemat biaya pada berbagai ambang kesediaan membayar.
020406080100050100150200250Ambang kesediaan membayar (juta rupiah per QALY)Peluang hemat biaya (%)75 juta225 juta100,0%

3. Analisis sensitivitas

Analisis sensitivitas satu arah. Sepuluh parameter dengan pengaruh terbesar terhadap manfaat moneter bersih.
-20-1001020interventions simvastatin 20 40 transition rate multipliers stable cvd on statin to post recurrent strokeinterventions simvastatin 20 40 tr...interventions simvastatin 20 40 transition rate multipliers stable cvd on statin to post recurrent miinterventions simvastatin 20 40 tr...interventions rosuvastatin 20 transition rate multipliers stable cvd on statin to post recurrent strokeinterventions rosuvastatin 20 tran...interventions rosuvastatin 20 transition rate multipliers stable cvd on statin to post recurrent miinterventions rosuvastatin 20 tran...interventions rosuvastatin 20 annual drug cost idrinterventions rosuvastatin 20 annu...transition rates annual stable cvd on statin to post recurrent stroketransition rates annual stable cvd...transition rates annual stable cvd on statin to post recurrent mitransition rates annual stable cvd...utility values new onset diabetesutility values new onset diabetesinterventions simvastatin 20 40 annual drug cost idrinterventions simvastatin 20 40 an...annual care costs idr post recurrent strokeannual care costs idr post recurre...Perubahan manfaat moneter bersih per pasien (juta rupiah)Parameter
  • Parameter pada nilai rendah
  • Parameter pada nilai tinggi

4. Analisis skenario

SkenarioSelisih QALYSelisih biayaRasio per QALY
Base case (30 yr)0,153Rp 813.575Rp 5,3 juta
5-year horizon0,006Rp 574.451Rp 103,4 juta
10-year horizon0,027Rp 510.760Rp 19,0 juta
20-year horizon0,093Rp 484.287Rp 5,2 juta
0% discount rate0,266Rp 1,2 jutaRp 4,6 juta
5% discount rate0,109Rp 672.925Rp 6,2 juta
Smaller real-world LDL gap between rungs (higher-intensity advantage halved): MI/stroke HR vs simvastatin moves toward 10,083Rp 2,1 jutaRp 25,5 juta
Rosuvastatin priced at upper retail (drug cost set to Rp 2.8m/yr, builder arm b assumption): decisive test of the cross-arm price gap on the frontier0,153Rp 30,9 jutaRp 201,8 juta
Stronger high-intensity new-onset-diabetes signal (rosuvastatin NODM multiplier raised toward CTT high-intensity RR 1.36)0,156Rp 1,3 jutaRp 8,4 juta

5. Validasi model

Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0000%).

Luaran pembandingPrediksi modelData terbitSumber
Annual recurrent myocardial-infarction incidence on statin (secondary prevention; comparator/simvastatin arm)2,2%2,3%CTT 2010 (Lancet) statin-arm annual major vascular event rate ~4.5/100 person-years (placebo 5.6/100py) in trials of est
Annual recurrent stroke incidence on statin (secondary prevention; comparator arm)1,8%1,8%Recurrent ischaemic stroke incidence in statin-treated secondary-prevention cohorts (CTT 2010 stroke component; SPARCL ~
New-onset diabetes annual incidence, older high-cardiometabolic-risk statin population (comparator/simvastatin arm)1,5%1,5%CTT IPD 2024 and JUPITER/WOSCOPS secondary analyses: incident diabetes ~1.5-3%/yr in older statin-treated cohorts with c
All-cause mortality at 15 years (established-ASCVD cohort from age 60, comparator/simvastatin arm)40,3%45,0%Indonesia life-table all-cause mortality for a cohort aged 60-75 plus established-ASCVD excess mortality (GBD Indonesia;

6. Penyesuaian untuk Indonesia

Uraian berikut tersedia dalam bahasa Inggris.

  • Current Fornas 2025 supports simvastatin and atorvastatin at FKTP. Rosuvastatin 10 mg is marked for PRB with a maximum of 60 tablets/month, so the policy question is expansion or step-up positioning rather than treating all three rungs as having identical access.
  • Current INAPROC extracts show a modest acquisition-price gap across the rungs, although rosuvastatin 20 mg requires two 10 mg tablets under the listed strength.
  • PERKI Panduan Tatalaksana Dislipidemia 2022 and international guidance (ESC/EAS 2019; ACC/AHA; NICE NG238) favour moderate-to-high-intensity statin therapy for established ASCVD, so the policy question is whether the incremental event reduction of higher-intensity rungs justifies the modest incremental drug cost and intensity-related harms.
  • Stroke (19.4%) and ischaemic heart disease (14.4%) are Indonesia's two leading causes of death (Kemenkes 2024), so even small per-patient absolute recurrent-event reductions scale to large averted events at the population level.
  • Reviewers should test the incremental-LDL and drug-price scenarios before interpreting the base-case sequential ICERs and the efficiency frontier.